RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Has this study been replicated?
The atlas records 1 replication of this study. Recorded outcomes: 1 failed. The earliest on record is from 2021.
Replications
- Replication Study: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Pelech et al. (2021). Outcome recorded: failed.
"The original study reported analogous results with GDC-0879, which was not observed in this replication."
Outcome read from the abstract. View paper
Cite this record
Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G., Morales, T., Aliagas, I., Liu, B., Sideris, S., Hoeflich, K. P., Jaiswal, B. S., Seshagiri, S., Koeppen, H., Belvin, M., … Malek, S. (2010). RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature, 464(7287), 431–435. https://doi.org/10.1038/nature08833
Other studies in the atlas
Failed replications · Successful replications · All browse pages